| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Devices and Research
News
|
Press Release:
Osmetech Licenses Roche Hot Start(R) Polymerase Technology
 This license allows Osmetech to include Hot Start(R) polymerase as part of the diagnostic kit providing Osmetech customers with a cost savings and level of convenience, and demonstrates Osmetech's diagnostic commitment of including everything in a kit rather than having the customer source and license components from various vendors.This latest license complements our highly sensitive electrochemical detection platform that is backed by an extensive patent portfolio, says Osmetech CEO James White. "We have over 145 granted patents worldwide,and several key in-licenses, built on acquisitions and collaborations with the likes of Harvard University, California Institute of Technology (Caltech), Motorola, Clinical Micro Sensors, Inc., University of North Carolina, Concordia University, Johns Hopkins University, University of Michigan, University of Washington, and Epidauros. This agreement with Roche will provide an added benefit for our customers who will not be required to obtain this license from Roche and pay Hot Start(R) polymerase royalties on tests performed when using Osmetech products." In 2006 Osmetech launched the eSensor(R) platform, an FDA cleared electrochemistry-based array system for cystic fibrosis carrier detection, and is currently in the process of completing its next generation instrument, the eSensor(R) XT8. Osmetech plans to seek FDA approval for and launch of this instrument with a CYP450/VKOR, a test to determine a patient's response to warfarin, later this year. The CYP450/VKOR assay is the first of many pharmacogenomic assays planned for the system, which is designed to meet the needs of the rapidly expanding field of personalized medicine. About Osmetech Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international molecular diagnostics business with operations in Boston and Pasadena in the US, serving the high growth, near patient testing market targeting small to medium sized hospitals. Osmetech has launched eSensor(R), an FDA cleared electrochemistry-based array system, for cystic fibrosis carrier detection and plan to launch a number of pharmacogenomic assays utilizing the same proprietary technology. More information: www.osmetech.com. Ticker: AIM LSE: OMH (London Stock Exchange)
NEWS SOURCE: Osmetech plc
Send2Press® is the originating wire service for this story. Terms of Use. © Osmetech plc. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Osmetech plc), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Osmetech plc.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Osmetech plc : » Osmetech Licenses Self-Assembling Monolayer (SAM) Technology to Minerva Biotechnologies Corporation » Osmetech Licenses Roche Hot Start(R) Polymerase Technology
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Osmetech Licenses Roche Hot Start(R) Polymerase Technology, Osmetech plc, Molecular Diagnostics, eSensor platform, diagnostics license, F. Hoffman LaRoche Ltd, Roche Molecular Systems Inc., Hot Start polymerase technology, nucleic acid diagnostic assays, eSensor XT8, response to warfarin, AIM LSE: OMH, press release, Jun 5, 2007. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 4021 times (1 today, 3 this week, 11 this month, 36 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)